Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617

Alison Birtle • 16 Feb 2021
GU Cancers 2021
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Antibodies Cabazitaxel Docetaxel Enfortumab vedotin

Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, shares her highlights from ASCO GU 2021, in particular discussing the promising results seen with studies of the antibody-drug conjugate enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617 versus cabazitaxel. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Alison Birtle, MRCP, FRCR, MD, has received research support from Sanofi Aventis, and has participated in advisory boards or provided educational support to Janssen, Astellas, Bayer, Roche, BMS, Pfizer, Sanofi Aventis and MSD.

More from Alison Birtle

3:52
Trial updates from ASCO GU 2021: SPIRE, NEO-BLADE, P3BEP and SAPROCAN
Alison Birtle • 16 Feb 2021
10:05
POUT: extended follow-up results
Alison Birtle • 16 Feb 2021
1:53
Alison Birtle: ASCO GU highlights
Alison Birtle • 13 Feb 2020
4:39
QoL impact of cystectomy
Alison Birtle • 13 Feb 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals